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Metabolic Syndrome and Incident Coronary
Heart Disease in Australian Indigenous
Populations
Ming Li1, Brad McCulloch2 and Robyn McDermott1
This report aims to compare the prediction of the metabolic syndrome (MetS) and its components for morbidity and
mortality of coronary heart disease (CHD) in a cohort of Australian Aboriginal and Torres Strait Islander adults (TSIs).
A total of 2,100 adults (1,283 Aborigines and 817 TSIs) was followed up for 6 years from 2000. Outcome measures
were all CHD events (deaths and hospitalizations). Baseline anthropometric measurements, blood pressure (BP),
fasting blood lipids and glucose were collected. Smoking and alcohol intake was self-reported. We found MetS was
more prevalent in TSI (50.3%) compared to Aborigines (33.0%). Baseline MetS doubled the risk of a CHD event in
Aborigines. Increased fasting triglycerides was stronger in predicting CHD (hazard ratio (HR): 2.8) compared with MetS
after adjusted for age, sex, tobacco and alcohol consumption, and baseline diabetes and albuminuria for Aborigines
but not among TSIs. MetS was not more powerful than its components in predicting CHD event. In Australian
Aborigines, the “triglyceridemic waist” phenotype strongly predicts CHD event, whereas among TSI, baseline diabetes
mediated the prediction of increased fasting glucose for CHD event.
Obesity (2012) 20, 1308–1312. doi:10.1038/oby.2011.156

Introduction

Metabolic syndrome (MetS) is a clustering of several risk factors including hypertension, dyslipidemia, impaired glucose
tolerance, and central adiposity. The clustering of those risk
factors confers a higher risk of diabetes and cardiovascular disease (CVD). The most recent International Diabetes Federation
(IDF) definition, similar to World Health Organization criteria,
relies on an ordering of criteria as an abnormal waist circumference (WC) must be present to satisfy for MetS (1,2); whereas the
Adult Treatment Panel III (ATPIII) of the National Cholesterol
Education Program proposed the definition of MetS as an
abnormality in any three of five criteria (3) (Table 1).
The prevalence of MetS in adult Australians was 28.6% in
1999–2000 in a nationally representative sample using the IDF
definition (4). Indigenous Australians had higher rates where
the ATPIII criteria classified 43% of Torres Strait Islander adults
(TSIs) and 44% of Aborigines with MetS, compared to 32 and
28%, respectively, according to World Health Organization
criteria, from a cross-sectional survey in North Queensland
during 1993–1995 (5). No studies in the Australian population
have been published to date to study the prediction of MetS for
CVD, although a meta-analysis of a dozen prospective studies from United States and European countries indicated MetS
independently conferred a modest risk (hazard ratio (HR):

1.3–1.7) of developing CVD, using both ATPIII of the National
Cholesterol Education Program or World Health Organization
criteria (6).
We have previously shown in this population that high baseline prevalence of diabetes and albuminuria better predict
incident CHD than the “traditional” Framingham risk factors
alone: BMI, blood pressure (BP), smoking, and dyslipidemia
(7). The aim of this analysis is to compare the prevalence of
MetS using IDF and ATPIII criteria, and to explore the independent prediction of components of MetS for developing
CHD in two distinct Australian indigenous populations from
North Queensland.
Methods and Procedures
Participants
The Well Persons Health Check (WPHC), conducted between 1998
and 2000, offered screening and referral services for people in discrete
indigenous communities in northern Queensland (8). A cohort of 2,100
indigenous people aged ≥15 without pre-existing heart conditions was
included in this study. The study was approved by the Cairns Base
Hospital Ethics Committee with support from relevant peak Aboriginal
and Torres Strait Islander Health Councils.
Baseline measurements
Details of the methods used in the WPHC have been published elsewhere (8). WC was recorded to the nearest centimeter with the latter
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Table 1 Criteria for the definition of the metabolic syndrome (IDF, NCEP-ATPIII)
WC

IDF

NCEP-ATPIII

≥94 cm (men), ≥80 cm (women)

≥102 cm (men), ≥88 cm (women)

Triglycerides

≥1.7 mmol/l or treatment

≥1.7 mmol/l or treatment

HDL

<1.03 mmol/l (men), <1.29 mmol/l (women)

<1.03 mmol/l (men), <1.29 mmol/l (women)

Blood pressure

≥135/86 mm Hg, or treatment of previously diagnosed
hypertension

≥135/86 mm Hg, or treatment of previously diagnosed
hypertension

Fasting glucose

≥5.6 mmol/l

≥5.6 mmol/l

According to the IDF 2005 definition, for a person to be defined as having MetS, one must have central obesity plus any two risk factors. NCEP-ATPIII is based on any
three of the risk factors.
HDL, high-density lipoprotein; IDF, International Diabetes Federation; NCEP-ATPIII, National Cholesterol Education Program–Adult Treatment Panel III; WC, waist
circumference.

measured by the same technician at the level of the umbilicus. Smoking
and alcohol intake was assessed by self-report questionnaire (9). Total
cholesterol, high-density lipoprotein (HDL), low-density lipoprotein
(LDL), triglycerides, and glucose were measured from the blood of
all participants after at least 8 hours fast. The blood was collected by a
medical officer, registered nurse, or trained phlebotomist in the early
morning. Blood glucose and blood lipids were measured using photometric enzyme end point assay with Cobas Integra 700/400 (Roche
Diagnostics, Rotkreuz, Switzerland). Albumin:creatinine ratio (ACR)
testing was performed routinely by immunoassay on all urine specimens that were collected in a sterile 50 ml container and refrigerated
at 4–8 °C immediately following collection (8). BP was the average of
three measurements taken in sitting position after 10 min rest.
Collection of hospitalization and death records
Hospitalization and death records for the WPHC participants were
matched using deterministic linkage based on hospital record numbers and clinical record numbers. A manual search of the Queensland
Health hospital records systems was conducted by a registered nurse
having experience working in the hospital records department. As
there is no universal unique patient identifiers within Queensland,
a mapping table linking WPHC reference number, hospital facility
code, and local unit record number was developed. This mapping
process commenced in January 2006 and was subsequently applied to
the Queensland Admitted Patient Data Collection, and hospitalization
relevant to the match unit record, facility code tuples were extracted.
Death matching was performed manually at the Queensland Registry
of Births, Deaths and Marriages.
Outcome determination
The census date for the study was determined as 1 January 2006, as
this marked the commencement of the mapping of WPHC numbers
to hospital unit record numbers. Any hospitalizations or deaths which
occurred subsequent to this date were disregarded.
Hospitalizations were considered to be CHD related if they contained
an ICD9-CM code commencing with 410, 411, 413, or 414 or an ICD9CM procedure code between 3,600 and 3,699, inclusive. For hospitalizations coded to ICD10, the diagnosis code range I20–I25, and procedure
code blocks 669–679, inclusive, were used.
Statistical analysis
All analyses were performed using STATA v10.1 (STATA, College
Station, TX).
Diabetes was defined as clinical diagnosis verified by the participant’s
medical records, or a 2-h glucose tolerance test result (blood glucose
level >11.1 mmol/l 2-h post glucose load), or fasting blood glucose level
(>7 mmol/l (10)). Albuminuria was defined having an abnormal spot
urine albumin:creatinine ratio ≥2.5 mg/mmol for males and ≥3.5 mg/
mmol for females (4).
MetS were categorized using both the IDF and ATPIII criteria based
on the available measurements of MetS components. The differences in
obesity | VOLUME 20 NUMBER 6 | june 2012

Table 2 Baseline characteristics of the Aboriginal and TSIs
from North Queensland
Aborigines
(N = 1283)

TSIs
(N = 817)

P value

Age (years)

36.6 (0.4)

37.9 (0.5)

0.02

Men, n (%)

620 (48.3)

433 (53.0)

0.04

Waist, men (cm)

89.4 (0.6)

101.3 (0.7)

<0.01

Waist, women (cm)

92.1 (0.6)

103.0 (0.8)

<0.01

Systolic BP (mm Hg)

128.3 (0.5)

133.8 (0.7)

<0.01

Diastolic BP (mm Hg)

71.9 (0.4)

70.8 (0.5)

0.05

Glucose (mmol/l)

5.4 (0.1)

6.1 (0.1)

<0.01

Triglycerides (mmol/l)

1.9 (0.04)

1.7 (0.04)

0.01

LDL (mmol/l)

2.9 (0.03)

3.2 (0.03)

<0.01

HDL (mg/mmol)

1.18 (0.01)

1.11 (0.09)

<0.01

ACR

15.5 (1.7)

14.4 (1.7)

0.7

Smokers (%)

822 (64.8)

415 (50.9)

<0.01

Drinkers (%)

902 (72.3)

514 (64.1)

<0.01

IDF MetS (%)

421 (33.0)

410 (50.3)

<0.01

Values are means (standard error) or no. (%); P value from t-tests for means and
χ2-tests for percentage.
ACR, albumin:creatinine ratio; HDL, high-density lipoprotein; IDF, International
Diabetes Federation; LDL, low-density lipoprotein; MetS, metabolic syndrome;
TSIs, Torres Strait Islander adults.

 aseline characteristics between the two indigenous groups were comb
pared using t-tests or χ2-tests. The prevalence of MetS and its components in the two subgroups were compared and the agreement κ was
calculated.
CHD cumulative incidence was calculated using the Kaplan–Meier
method for a range of population strata by MetS and its components.
HRs were calculated using a Cox proportional hazards model and
adjusted for sex, age, smoking and drinking status, diabetes, and albuminuria to explore the independent predictive effect of MetS. The statistical significance level was set as P < 0.05.
Results

The baseline health profile differs significantly between the two
indigenous groups. TSIs had significantly higher WC, systolic
BP, fasting blood glucose, LDL but lower triglycerides, HDL,
albumin:creatinine ratio, and behavioral risks including smoking and drinking alcohol (Table 2).
The baseline prevalence of MetS and its components defined
by IDF and ATPIII in the two ethnic groups are summarized
1309
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Table 3 Prevalence of metabolic syndrome and components
(IDF, NCEP-ATPIII criteria) by ethnicity
IDF

NCEP-ATPIII

1,277

1,283

Raised WC, n (%)

723 (56.6)

496 (38.8)

Raised BP, n (%)

570 (44.6)

570 (44.4)

Raised blood glucose, n (%)

240 (19.4)

240 (18.7)

Low HDL, n (%)

603 (51.9)

603 (47.0)

Raised triglycerides, n (%)

490 (39.5)

490 (38.2)

MetS, n (%)

421 (33.0)

400 (31.2)

Aborigines, n

TSIs, n

816

817

Raised WC, n (%)

652 (79.9)

522 (64.0)

Raised BP, n (%)

452 (55.5)

452 (55.3)

Raised blood glucose, n (%)

225 (28.2)

225 (27.5)

Low HDL, n (%)

457 (57.8)

457 (55.9)

Raised triglycerides, n (%)

281 (35.2)

281 (34.4)

MetS, n (%)

410 (50.3)

383 (46.9)

In Aborigines, agreement of MetS between the two definition was 90.9%, κ was
0.79, P < 0.001. In TSIs, agreement of MetS was 94.7%, κ was 0.89, P < 0.001.
BP, blood pressure; HDL, high-density lipoprotein; IDF, International Diabetes
Federation; MetS, metabolic syndrome; NCEP-ATPIII, National Cholesterol Education Program–Adult Treatment Panel III; TSIs, Torres Strait Islander adults;
WC Waist circumference.

in Table 3. Compared with ATPIII MetS criteria, the IDF definition classified the same prevalence of MetS (33% vs. 31% in
Aborigines and 50.3% vs. 46.9% in TSIs) and its components.
The percentage of agreement of the two definitions was 90.9%
in Aborigines and 94.7% in TSIs and the κ statistic was 0.79 in
Aborigines (P < 0.001) and 0.89 in TSIs (P < 0.001).
A total of 151 CHD events (deaths and hospitalizations) were
identified during a mean of 6.0 years of follow-up among the
2,100 eligible subjects. A total crude CHD incidence rate was
similar in the two groups: 11.9 cases/1,000 person years (py)
(12.6 cases/1,000 py; 95% confidence interval: 10.3–15.3 for
Aborigines compared with 10.9/1,000 py; 95% confidence interval: 8.3–14.3 in TSIs). Among Aborigines, the CHD incidence
rate in those classified as having MetS was 20.0 cases/1,000 py
compared with 8.9 cases/1,000 py in normal groups. Among
TSIs, the incidence rate in MetS patients was 16.3 cases/1,000
py compared with 5.7 cases/1,000 py in normal subjects. The
CHD incidence rates by MetS components in the two groups
are summarized in Tables 4 and 5. Among the Aborigines,
higher CHD incidence rate was associated with higher WC,
hypertension, increased blood fasting glucose, triglycerides
and combined hypertriglycerides and waist; whereas in TSIs,
the significant MetS components predicting CHD were raised
BP and raised fasting glucose. Baseline diabetes and albuminuria were strong predictors of CHD incidence in both groups
(HR for diabetes 3.2, HR for albuminuria 3.4 P < 0.001 (7)).
After adjusting for age, sex, smoking and drinking status,
baseline diabetes, and albuminuria, Aborigines with MetS
were approximately twice as likely to develop CHD. Increased
WC remained associated with CHD incidence. The predictive
1310

Table 4 Incidence of CHD and its association with IDF MetS
among Aborigines from North Queensland
Incidence rate
case/1,000 py
(95% CI)

Crude HR
(95% CI)

Adjusted HRa
(95% CI)

No

8.9 (6.7–11.8)

1.0

1.0

Yes

20.0 (15.2–26.4)

2.3 (1.5–3.4)

1.9 (1.1–3.3)

MetS

Raised waist
No

9.6 (6.9–13.6)

1.0

1.0

Yes

14.7 (11.5–18.8)

1.5 (1.0–2.3)

1.8 (1.0–3.2)

Yes

16.0 (12.0–21.3)

1.5 (1.0–2.3)

1.8 (1.02–3.2)

No

8.0 (5.7–11.1)

1.0

1.0

Yes

18.2 (14.2–23.4)

2.3 (1.5–3.5)

1.5 (0.8–2.6)

Raised BP

Raised blood glucose
No

10 (7.7–12.8)

1.0

Yes

23.4 (16.6–32.9)

2.4 (1.5–3.6)

1.3 (0.6–2.8)

Low HDL
No

12.3 (9.0–16.7)

1.0

1.0

Yes

14.1 (10.7–18.6)

1.1 (0.7–1.7)

0.9 (0.5–1.5)

Raised triglycerides
No

7.2 (5.1–10.1)

1.0

1.0

Yes

21.1 (16.4–27.1)

2.9 (1.9–4.5)

2.8 (1.6–4.8)

Raised triglycerides and waist
None

7.3 (4.6–11.6)

1.0

1.0

Either

10.1 (7.1–14.4)

1.4 (0.8–2.5)

1.6 (0.7–3.8)

Both

21.9 (16.4–29.3)

3.0 (1.7–5.1)

3.6 (1.6–8.1)

CI, confidence interval; CHD, coronary heart disease; IDF, International Diabetes
Federation; MetS, metabolic syndrome; HR, hazard ratio; py, person years.
a
Adjusting for age, sex, smoking and drinking status, diabetes, and albuminuria.

effects of hypertension and increased blood glucose were
attenuated to null after adjustment, however, those with raised
triglycerides were 2.8 times more likely to develop CHD during the 6-year follow-up. The combined increased triglycerides and WC independently predicted CHD incidence in
Aborigines (HR: 3.6, 95% confidence interval: 1.6–8.1), while
those with increased triglycerides but normal waist or those
with increased waist but normal triglycerides did not predict CHD morbidity and mortality (Table 4). In TSIs, after
adjustment, neither MetS nor its components predicted CHD
incidence.
Discussion

We found in this population a high baseline prevalence of
MetS, by both IDF and ATPIII criteria (31–33% in Aborigines
and 47–50% in TSI) compared to the general Australian (28.6%
(4)) and the US (32%) populations (11). The higher MetS prevalence among TSI was attributable mainly to higher WC and
fasting glucose compared to Aborigines. Yet incidence of CHD
was similar for both groups and there were no sex differences.
VOLUME 20 NUMBER 6 | june 2012 | www.obesityjournal.org
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Table 5 Incidence of CHD and its association with IDF MetS
among TSIs from North Queensland
Incidence rate
case/1,000 py
(95% CI)

Crude HR
(95% CI)

Adjusted HRa
(95% CI)

No

5.7 (3.4–9.6)

1.0

1.0

Yes

16.3 (11.9–22.3)

2.9 (1.6–5.3)

1.0 (0.5–2.3)

MetS

Raised waist
No

4.9 (2.1–11.9)

1.0

1.0

Yes

12.5 (9.4–16.6)

1.6 (1.0–6.5)

1.5 (0.4–6.7)

Raised blood pressure
No

6.9 (4.2–11.4)

1.0

1.0

Yes

14.2 (10.4–19.6)

2.1 (1.1–3.8)

0.7 (0.3–1.4)

Raised blood glucose
No

6.6 (4.4–10.0)

1.0

1.0

Yes

21.8 (15.0–31.5)

3.3 (1.9–5.8)

0.6 (0.2–2.2)

Low HDL
No

9.2 (5.8–14.6)

1.0

1.0

Yes

12.0 (8.5–16.9)

1.3 (0.7–2.3)

1.1 (0.6–2.1)

Raised triglycerides
No

8.4 (5.7–12.4)

1.0

1.0

Yes

14.9 (10.1–22.1)

1.8 (1.0–3.1)

1.1 (0.6–2.1)

CI, confidence interval; CHD, coronary heart disease; IDF, International Diabetes
Federation; MetS, metabolic syndrome; HR, hazard ratio; py, person years.
a
Adjusting for age, sex, smoking and drinking status, diabetes, and albuminuria.

Ethnic-specific cut-offs for WC or other anthropometric measurements may be needed for these populations when assessing
health risks. A study using receiver operating characteristic
analysis to assess the discrimination power of BMI, WC, and
waist/hip ratio for cardiometabolic risks among these populations showed neither BMI nor WC was better than waist/hip
ratio (12).
MetS has been shown to strongly predict diabetes incidence
in this population, with an adjusted HR of 2.7 in Aborigines
and 2.9 in TSIs compared with absence of the MetS at baseline (13). MetS predicts CHD morbidity and mortality in US
and European populations with varied HRs due to varied
adjustment of other risk factors and different methods used
to classify MetS (6). For example, the Framingham Offspring
study showed that a cluster of any three out of six risk factors
including the sex-specific lowest quintile HDL, highest quintile
of BMI, systolic BP, triglycerides, glucose, and serum total cholesterol was associated with a 2.4 and 5.9 times increased risk
of CHD in men and women, respectively (14). The European
studies show adjusted hazard ratios for CHD mortality were 1.5
in men and 2.5 in women with the MetS (15).
The prediction of MetS components for CHD among the two
indigenous groups also varied, although HDL in both groups
did not significantly predict CHD morbidity and mortality.
Among Aborigines, increased triglycerides was the strongest
independent predictor (HR: 2.8) followed by increased waist
obesity | VOLUME 20 NUMBER 6 | june 2012

(HR: 1.8). This result is consistent with that from a meta-analysis of 10,158 incident cases among 262,525 participants in
29 western prospective studies (16) and another meta-analysis among 96,224 individuals from 26 studies in Asia-Pacific
region (17). Both studies reported the top tertile or quintile
triglycerides conferred 1.6–1.8 times increased risk of CHD
morbidity and mortality after adjustment for other known
cardiovascular risk factors including fasting glucose, total and
HDL cholesterol.
Other studies have analyzed the prevalence of the hypertriglyceridemic waist phenotype and its association with
type 2 diabetes and CVDs, indicating it could be a simpler
alternative to MetS for CHD risk identification, especially
among young people, before other MetS components appear
clinically (18,19).
Aboriginal and TSI people experience disadvantage across
a range of socioeconomic indicators including education,
employment, income and housing (20). In 2004–2005, half of
the adult indigenous population were current daily smokers.
The proportion of indigenous adults drinking alcohol at high
risk levels increased from 12% in 2001 to 17% in 2004–2005
(20). More than half (57%) of indigenous people aged ≥15
years were overweight or obese. Between 1995 and 2004–2005,
rates of overweight/obesity among indigenous people aged ≥15
years increased from 48% to 56% (20).
In summary, this study showed that MetS did not predict CHD as strongly as its components. In Aborigines, the
combined increased triglycerides and WC better predicts
incident CHD, whereas in TSIs, baseline diabetes and albuminuria could be used to detect those at risk. In both populations, greater attention is needed to alleviate risk behaviors
and conditions, including improving the quality of the food
supply.
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